ARKG — ARK Genomic Revolution ETF

ARKG Price Performance — Growth of $10,000

Value of a $10,000 investment in ARKG over time, compared with SPY. Both lines are rebased to $10,000 on the first shared date. Based on total returns — prices are adjusted for dividends and splits, so this assumes distributions were reinvested. Hover or tap the chart for exact values.

ARKG Drawdown

The "underwater" chart: ARKG's decline from its highest prior value at each point in time. It shows how deep past losses ran and how long the fund took to recover to break-even.

Overview

The ARK Genomic Revolution ETF (ARKG) is a Healthcare sector fund issued by ARK ETF Trust with $1.73 billion in assets under management. Trading at $37.50 per share, the fund holds an overall rank of #377 out of 458 tracked ETFs across all categories and carries an ETFValuer grade of C with a score of 50.8 out of 100. Investors face an annual expense ratio of 0.75% and receive no dividend income, as the current yield stands at 0.00%. This fund is one of 11 ETFs tracked within the Healthcare category by ETFValuer. The combination of a mid-tier grade and a substantial asset base suggests significant investor adoption despite the fund's middling overall ranking. The absence of dividend yield indicates a focus on capital appreciation rather than income generation for shareholders.

Recent price action shows a decline of 0.85% over the last day and a 3.47% drop over the past week, followed by a sharper 11.47% loss in the last month. Despite these short-term setbacks, the fund has demonstrated strong momentum over longer horizons with a 26.77% gain in the last three months and a 15.67% increase over six months. Year-to-date returns have accelerated to +28.51%, while the one-year return stands at +46.03%. Over a three-year period, the fund has delivered a cumulative return of +10.42%. This pattern illustrates a divergence where short-term volatility contrasts with robust long-term growth, particularly evident in the one-year performance compared to the three-year average.

The fund exhibits a volatility label of Very High, supported by a beta of 2.38 which indicates price movements that are more than double the market's sensitivity. This high sensitivity is reflected in a maximum drawdown of -51.74%, showing the extent of potential losses during market downturns. Despite the elevated risk profile, the Sharpe ratio of 0.95 suggests that the returns generated have been sufficient to compensate for the volatility experienced. The combination of a 2.38 beta and a -51.74% max drawdown implies the fund amplifies market swings in both directions. Investors should expect significant price fluctuations, yet the positive Sharpe ratio indicates that the fund has historically provided a reasonable risk-adjusted return relative to its high volatility.

AI-generated summary based on the data on this page.

ARKG Top Holdings

Holdings as of 2026-04-30 per the fund's most recent SEC N-PORT-P filing. Top 10 holdings make up 58.8% of net assets — a rough gauge of concentration risk (the higher this figure, the more the fund's return depends on a handful of names). To see how ARKG's holdings overlap with other ETFs you own or are considering, check the Stock Overlap tool.

Which Funds Overlap With ARKG

Holding two funds that own the same companies adds cost and complexity without adding much diversification. These tracked ETFs share the most names with ARKG's top 10 — ARKK overlaps most, holding 2 of the same companies as ARKG's top 10 (18.3% of ARKG's assets).

Compares the top 10 reported holdings of each fund, so it's a floor on true overlap — two S&P 500 trackers overlap ~100% even when only 10 names are listed. Use the Stock Overlap tool to search by individual company.

Market Backdrop

10-Year Treasury Yield: 4.61% (as of 2026-07-28) — The yield on 10-year US Treasury bonds — the standard "risk-free rate" benchmark used to contextualize this fund’s Sharpe ratio and returns.

CBOE Volatility Index (VIX): 18.21 (as of 2026-07-28) — A real-time gauge of expected S&P 500 volatility over the next 30 days — useful context for this fund’s own volatility label.

Federal Funds Rate: 3.63% (as of 2026-06-01) — The Federal Reserve’s target policy rate, which anchors short-term borrowing costs across the economy.

ARKG Liquidity, Domicile & Tax Treatment

Liquidity: Quoted bid/ask spread is 0.05% and average daily volume is 3.3M/day. Tighter spreads and higher volume mean lower round-trip trading costs; this is a live-market snapshot and can widen during volatile sessions. AUM of $1.73B provides ample scale, supporting tight spreads and issuer commitment to keep the fund open.

Domicile & tax treatment: ARKG is a US-domiciled, SEC-registered ('40 Act) exchange-traded fund. Dividends and capital gains distributions are reported to US investors on Form 1099-DIV, and the fund is not subject to the PFIC reporting or UCITS-specific rules that apply to Irish- or Luxembourg-domiciled funds. Non-US investors should note that US-domiciled ETFs are generally subject to 30% US withholding tax on dividends (unless reduced by treaty) and to US estate tax exposure on the position — Irish-domiciled UCITS ETFs tracking the same index often avoid both, which is why non-US residents frequently prefer the UCITS equivalent where one exists. This is general information, not tax advice — consult a tax professional for your situation.

ARKG Performance History

How ARKG Compares to Other Healthcare ETFs